Results 101 to 110 of about 1,696 (185)

CytoSorb®-Anwendung : Assoziation mit klinischem Outcome in der Herzchirurgie

Das Auftreten eines systemisch inflammatorischen Response-Syndroms (SIRS) im Rahmen eines herzchirurgischen Eingriffes steht bei Persistenz im Zusammenhang mit einer erhöhten Morbidität und Mortalität.
Biehler, Natalie
core   +1 more source

Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment

, 2018
We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure.
VD Dhokia, D Madhavan, Craig G Morris, A Austin   +3 more
core   +1 more source

The use of CytoSorb therapy in COVID-19 cytokine storm

, 2021
The CytoSorb whole blood adsorber is a CE approved medical device for the extracorporeal removal of cytokines. The aim is to reduce excessive cytokine levels and other inflammatory mediators, while maintaining the physiological immune response. It is documented in the literature that critically ill patients with COVID-19 had the increased levels of ...
openaire   +1 more source

The Effect of Hemoadsorption with CytoSorb on Severe COVID-19 Complications

Общая реаниматология
The aim of the study was to assess the effect of hemoadsorption with CytoSorb on the inflammatory response, respiratory failure, and mortality in patients with severe novel coronavirus infection.Materials and methods.
A. S. Rybalko, S. N. Galkina, A. S. Saryglar, A. V. Voronin, M. I. Rezyapova, N. I. Chaus, S. N. Perekhodov, N. A. Karpun   +7 more
doaj   +1 more source

2025 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley   +1 more source

Cytosorb treatment in severe COVID-19 cardiac and pulmonary disease [PDF]

European Heart Journal - Case Reports, 2021
Michele Ciabatti, Lucia Martinese, Antonio Quacquarelli, Maurizio Pieroni, Marco Feri, Leonardo Bolognese   +5 more
openaire   +2 more sources

Ticagrelor removal by CytoSorb® in patients requiring emergent or urgent cardiac surgery: a UK-based cost-utility analysis

, 2019
Background: Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes.
Mortensen, E, Branagan‑Harris, M, Preissing, F, Adam, D, Rahimi, Kazem, Javanbakht, M, Rahimi, K, Trevor, M, Scheier, J, Cook, SF, Rezaei Hemami, M, Degener, F   +11 more
core   +1 more source

Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

Journal of Cardiothoracic Surgery
Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency situations, and the ...
Vitor Mendes, Jaid Mamode, Jalal Jolou, Mourad Malki, Christoph Ellenberger, Mustafa Cikirikcioglu, Christoph Huber   +6 more
doaj   +1 more source

Use of Cytosorb methods in septic conditions in intesive care units [PDF]

, 2018
Sepsa je po život opasna disfunkcija organa uzrokovana nereguliranim odgovorom domaćina. Umjesto lokalne upale uzrokovane lokalnom infekcijom, što bi bio adekvatan odgovor, cijeli organizam reagira upalom, ozljeđujući vlastita tkiva i organe.
Draganić, Štefanija
core  

Ticagrelor Removal by CytoSorb\uae in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis

, 2020
\ua9 2019, The Author(s).Background: Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes.
Javanbakht M, Branagan-Harris M, Cook SF, Mortensen E, Rahimi K, Rezaei Hemami M, Trevor M, Adam D, Preissing F, Scheier J, Degener F   +10 more
core